LN LNTH Lantheus Holdings, Inc. Loading... : Investor Sentiment and Bull/Bear Views

Author believes Lantheus is an undervalued biotech cash cow play, with a pipeline the market is missing. The FDA recently approved a new PYLARIFY formulation expected to increase batch sizes, reach more patients and serve broader geographic markets, supporting the leading PSMA PET imaging agent used in over 760,000 scans. NEURACEQ sales grew from about $20 million to $31 million quarter-over-quarter, and the author expects it to become a blockbuster given the growing dementia crisis and Lantheus's strong sales team. Main risk not explicitly stated beyond general biotech pipeline execution.

FDA approved a new formulation for PYLARIFY to increase batch sizes, and NEURACEQ sales recently jumped from $20 million to $31 million quarter-over-quarter. The new PYLARIFY formulation will expand geographic reach, while the growing US dementia crisis will turn NEURACEQ into a blockbuster product, driving significant revenue. Buy LNTH as an undervalued biotech play with a proven sales team and highly successful medical imaging products. Slower than expected adoption of NEURACEQ, competition from other imaging agents, or unforeseen regulatory hurdles.